TY - JOUR
T1 - Extracorporeal treatment for ethylene glycol poisoning
T2 - systematic review and recommendations from the EXTRIP workgroup
AU - for the EXTRIP workgroup
AU - Ghannoum, Marc
AU - Gosselin, Sophie
AU - Hoffman, Robert S.
AU - Lavergne, Valery
AU - Mégarbane, Bruno
AU - Hassanian-Moghaddam, Hossein
AU - Rif, Maria
AU - Kallab, Siba
AU - Bird, Steven
AU - Wood, David M.
AU - Roberts, Darren M.
AU - Alhatali, Badria
AU - Anseeuw, Kurt
AU - Berling, Ingrid
AU - Bouchard, Josée
AU - Bunchman, Timothy E.
AU - Calello, Diane P.
AU - Chin, Paul K.
AU - Doi, Kent
AU - Galvao, Tais
AU - Goldfarb, David S.
AU - Hoegberg, Lotte C.G.
AU - Kebede, Sofia
AU - Kielstein, Jan T.
AU - Lewington, Andrew
AU - Li, Yi
AU - Macedo, Etienne M.
AU - MacLaren, Rob
AU - Mowry, James B.
AU - Nolin, Thomas D.
AU - Ostermann, Marlies
AU - Peng, Ai
AU - Roy, Jean Philippe
AU - Shepherd, Greene
AU - Vijayan, Anitha
AU - Walsh, Steven J.
AU - Wong, Anselm
AU - Yates, Christopher
N1 - Funding Information:
EXTRIP received support consisting of an unrestricted grant of $60,633 Canadian from the Verdun Research Fund (the institution of M. Ghannoum) solely for the reimbursement of travel expenses for the in-person guideline meeting and payment to dedicated translators for retrieval and translation of foreign language articles.
Funding Information:
All prospective members were required to disclose any actual, potential, or perceived conflict of interest before inclusion in the workgroup. The disclosures were used to categorize the members as cleared for full participation, allowed to participate with recusal from certain aspects of guideline development, or disqualified from participation. The cochairs remained free of any financial conflict of interest during the entire guideline development process, meaning avoidance of interests and relationships with pharmaceutic or device companies pertaining to the topic of poisoning. Members were required to disclose to the cochairs any new activities that had the potential to be viewed as a conflict of interest before engaging in the activity, at the beginning of face-to-face meeting, and before submission of the manuscript. Cochairs determined if specific activities were allowed under the conflict-of-interest rules. All conflicts of interest deemed as potential appearance of a conflict of interest were required to be included in the manuscript. M. Ghannoum is a scholar of the Fonds de Recherche du Quebec–Santé, reports employment with the Government of Quebec, and serves as EXTRIP chair. R.S. Hoffman reports honoraria from UpToDate. V. Lavergne reports employment with the Infectious Diseases Society of America. D.M. Wood reports employment with Guy’s and St Thomas’ NHS Foundation Trust; research funding from the European Monitoring Centre for Drugs and Drug Addiction; honoraria from the European Monitoring Centre for Drugs and Drug Addiction and the United Nations Office on Drugs and Crime; and serving as a scientific advisor member of the European Association of Poisons Centres and Clinical Toxicologists, the European Monitoring Centre for Drugs and Drug Addiction, the Journal of Medical Toxicology, the UK Advisory Council on the Misuse of Drugs, and the United Nations Office on Drugs and Crime. All remaining authors have nothing to disclose.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Ethylene glycol (EG) is metabolized into glycolate and oxalate and may cause metabolic acidemia, neurotoxicity, acute kidney injury (AKI), and death. Historically, treatment of EG toxicity included supportive care, correction of acid–base disturbances and antidotes (ethanol or fomepizole), and extracorporeal treatments (ECTRs), such as hemodialysis. With the wider availability of fomepizole, the indications for ECTRs in EG poisoning are debated. We conducted systematic reviews of the literature following published EXTRIP methods to determine the utility of ECTRs in the management of EG toxicity. The quality of the evidence and the strength of recommendations, either strong (“we recommend”) or weak/conditional (“we suggest”), were graded according to the GRADE approach. A total of 226 articles met inclusion criteria. EG was assessed as dialyzable by intermittent hemodialysis (level of evidence = B) as was glycolate (Level of evidence = C). Clinical data were available for analysis on 446 patients, in whom overall mortality was 18.7%. In the subgroup of patients with a glycolate concentration ≤ 12 mmol/L (or anion gap ≤ 28 mmol/L), mortality was 3.6%; in this subgroup, outcomes in patients receiving ECTR were not better than in those who did not receive ECTR. The EXTRIP workgroup made the following recommendations for the use of ECTR in addition to supportive care over supportive care alone in the management of EG poisoning (very low quality of evidence for all recommendations): i) Suggest ECTR if fomepizole is used and EG concentration > 50 mmol/L OR osmol gap > 50; or ii) Recommend ECTR if ethanol is used and EG concentration > 50 mmol/L OR osmol gap > 50; or iii) Recommend ECTR if glycolate concentration is > 12 mmol/L or anion gap > 27 mmol/L; or iv) Suggest ECTR if glycolate concentration 8–12 mmol/L or anion gap 23–27 mmol/L; or v) Recommend ECTR if there are severe clinical features (coma, seizures, or AKI). In most settings, the workgroup recommends using intermittent hemodialysis over other ECTRs. If intermittent hemodialysis is not available, CKRT is recommended over other types of ECTR. Cessation of ECTR is recommended once the anion gap is < 18 mmol/L or suggested if EG concentration is < 4 mmol/L. The dosage of antidotes (fomepizole or ethanol) needs to be adjusted during ECTR.
AB - Ethylene glycol (EG) is metabolized into glycolate and oxalate and may cause metabolic acidemia, neurotoxicity, acute kidney injury (AKI), and death. Historically, treatment of EG toxicity included supportive care, correction of acid–base disturbances and antidotes (ethanol or fomepizole), and extracorporeal treatments (ECTRs), such as hemodialysis. With the wider availability of fomepizole, the indications for ECTRs in EG poisoning are debated. We conducted systematic reviews of the literature following published EXTRIP methods to determine the utility of ECTRs in the management of EG toxicity. The quality of the evidence and the strength of recommendations, either strong (“we recommend”) or weak/conditional (“we suggest”), were graded according to the GRADE approach. A total of 226 articles met inclusion criteria. EG was assessed as dialyzable by intermittent hemodialysis (level of evidence = B) as was glycolate (Level of evidence = C). Clinical data were available for analysis on 446 patients, in whom overall mortality was 18.7%. In the subgroup of patients with a glycolate concentration ≤ 12 mmol/L (or anion gap ≤ 28 mmol/L), mortality was 3.6%; in this subgroup, outcomes in patients receiving ECTR were not better than in those who did not receive ECTR. The EXTRIP workgroup made the following recommendations for the use of ECTR in addition to supportive care over supportive care alone in the management of EG poisoning (very low quality of evidence for all recommendations): i) Suggest ECTR if fomepizole is used and EG concentration > 50 mmol/L OR osmol gap > 50; or ii) Recommend ECTR if ethanol is used and EG concentration > 50 mmol/L OR osmol gap > 50; or iii) Recommend ECTR if glycolate concentration is > 12 mmol/L or anion gap > 27 mmol/L; or iv) Suggest ECTR if glycolate concentration 8–12 mmol/L or anion gap 23–27 mmol/L; or v) Recommend ECTR if there are severe clinical features (coma, seizures, or AKI). In most settings, the workgroup recommends using intermittent hemodialysis over other ECTRs. If intermittent hemodialysis is not available, CKRT is recommended over other types of ECTR. Cessation of ECTR is recommended once the anion gap is < 18 mmol/L or suggested if EG concentration is < 4 mmol/L. The dosage of antidotes (fomepizole or ethanol) needs to be adjusted during ECTR.
KW - CKRT
KW - EXTRIP
KW - Ethylene glycol
KW - Hemodialysis
KW - Poisoning
UR - https://www.scopus.com/pages/publications/85147893606
U2 - 10.1186/s13054-022-04227-2
DO - 10.1186/s13054-022-04227-2
M3 - Article
C2 - 36765419
AN - SCOPUS:85147893606
SN - 1364-8535
VL - 27
JO - Critical Care
JF - Critical Care
IS - 1
M1 - 56
ER -